While Empagliflozin, as an SGLT2 inhibitor, has also been reported to have inhibitory effects on cancer cells, such as cervical cancer [17], breast cancer [18], hepatocellular carcinoma(HCC) [19], and lung cancer [2]. Here, SLC5A2 is linked to lung carcinoma.